Such agonist therapy is under development and one promising candidate, GB1275, is currently in its first clinical phase at the beginning of 2023. This agonist of CD11b shows impaired transmigration of suppressive TAMs into the site of tumour and modulation of TAMs towards pro-inflammatory phenotype with higher antigen presentation and production of pro-inflammatory cytokines.
Agonist therapy targeting CD11b is under development, with GB1275 being a promising candidate currently in its initial clinical trial stage at the start of 2023. This CD11b agonist inhibits the movement of suppressive tumor-associated macrophages (TAMs) into the tumor site and alters TAMs towards a pro-inflammatory phenotype, enhancing antigen presentation and cytokine production.